With 100,000 patients in the U.S. and leading therapies like Casgevy, Lyfgenia, Adakveo, and Reblozyl, North America captured 56.3% of the global market in 2024 . https://www.datamintelligence.com/research-report/sickle-cell-disease-treatment-market